Jun 22, 2020
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Jun 08, 2020
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
May 06, 2020
Compugen Reports First Quarter 2020 Results
Apr 27, 2020
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
Mar 26, 2020
Innoplexus Announces Major Findings in Potential Combination Therapies for COVID-19
Mar 18, 2020
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
Mar 16, 2020
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Nov 08, 2019
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 31, 2019
OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology
Sep 19, 2019
Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS
Jul 17, 2019
Novel Immuno-Oncology Biomarker Testing Market, 2019-2030
Jun 05, 2019
RNA Therapies in Oncology Analytical Tool: 127 Companies, 274 RNA Therapy Drugs, 182 in Active Development in Cancer Across 122 Different Targets
Apr 11, 2019
Gene Therapy in Oncology: Innovation to Commercialization, Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions by DelveInsight
Apr 09, 2019
IO Combinations 360° Summit Announces Keynotes and Program Line-Up for the 4th Annual Event
Apr 01, 2019
Leap Therapeutics Reports Clinical Update and 2018 Financial Results
Feb 26, 2019
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
Jan 22, 2019
OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019
Nov 01, 2018
Infinity Announces IPI-549 Late-Breaking Presentation at SITC 33rd Annual Meeting
Jun 04, 2018
Infinity Reports IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study at American Society of Clinical Oncology Annual Meeting
May 08, 2018
Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results